UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 532

Sortiert nach

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Annals of oncology, 2019-12, Vol.30 (12), p.1902-1913

2019

Link zum Volltext

Verfügbarkeit prüfen

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

Leukemia, 2018-02, Vol.32 (2), p.429-437

2018

Link zum Volltext

Verfügbarkeit prüfen

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)

Annals of oncology, 2018-10, Vol.29, p.viii737-viii737

2018

Link zum Volltext

Verfügbarkeit prüfen

The real-world impact of modern treatments on the survival of patients with metastatic melanoma

Annals of oncology, 2018-10, Vol.29, p.viii456-viii456

2018

Link zum Volltext

Verfügbarkeit prüfen

EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma

Annals of oncology, 2018-10, Vol.29, p.viii459-viii459

2018

Link zum Volltext

Verfügbarkeit prüfen

Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma

Clinical and experimental immunology, 2006-04, Vol.144 (1), p.76-84

2006

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

Annals of oncology, 2018-10, Vol.29, p.viii465-viii465

2018

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Annals of oncology, 2019-07, Vol.30 (7), p.1154-1161

2019

Link zum Volltext

Verfügbarkeit prüfen

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

Annals of oncology, 2022-01, Vol.33 (1), p.6-12

2022

Link zum Volltext

Verfügbarkeit prüfen

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

Leukemia, 2016-12, Vol.30 (12), p.2413-2416

2016

Link zum Volltext

Verfügbarkeit prüfen

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer

Molecular oncology, 2015-12, Vol.9 (10), p.1918-1935

2015

Link zum Volltext

Verfügbarkeit prüfen

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

Annals of oncology, 2018-07, Vol.29 (7), p.1575-1581

2018

Link zum Volltext

Verfügbarkeit prüfen

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR⁻/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

Scandinavian journal of immunology, 2010-12, Vol.72 (6), p.540-547

2010

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress

Annals of oncology, 2017-12, Vol.28, p.xi27-xi28

2017

Link zum Volltext

Verfügbarkeit prüfen

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Leukemia, 2017-02, Vol.31 (2), p.495-498

2017

Link zum Volltext

Verfügbarkeit prüfen

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

Leukemia, 2014-01, Vol.28 (1), p.236-238

2014

Link zum Volltext

Verfügbarkeit prüfen

Serological assessment of extracellular matrix (ECM) remodeling in relation to clinical response in metastatic melanoma patients treated with ipilimumab

Annals of oncology, 2017-12, Vol.28, p.xi10-xi10

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Comparison of 'Standard' and 'Young' Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

Scandinavian journal of immunology, 2012-02, Vol.75 (2), p.157-167

2012

Link zum Volltext

Verfügbarkeit prüfen

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma

Immuno-oncology technology, 2023-12, Vol.20, p.100396-100396, Article 100396

2023

Link zum Volltext

Verfügbarkeit prüfen

T cell therapy for patients with advanced ovarian cancer: a pilot study in progress

Annals of oncology, 2016-10, Vol.27, p.vi375-vi375

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients

Annals of oncology, 2018-10, Vol.29, p.viii402-viii402

2018

Link zum Volltext

Verfügbarkeit prüfen

T cell recognition of breast cancer antigens

Annals of oncology, 2017-12, Vol.28, p.xi19-xi19

2017

Link zum Volltext

Verfügbarkeit prüfen

Functional characterization of Foxp3-specific spontaneous immune responses

Leukemia, 2013-12, Vol.27 (12), p.2332-2340

2013

Link zum Volltext

Verfügbarkeit prüfen

Cellular based cancer vaccines: type 1 polarization of dendritic cells

Current medicinal chemistry, 2012-09, Vol.19 (25), p.4239

2012

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin‐Expressing Cells

Scandinavian journal of immunology, 2016-09, Vol.84 (3), p.191-193

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 532

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(474)
Mit Volltextzugriff
(501)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(310)
Life Sciences & Biomedicine
(203)
Humans
(164)
Female
(98)
Physical Sciences
(96)
Physics
(91)
Male
(74)
Biological And Medical Sciences
(69)
Middle Aged
(68)
Physics, Condensed Matter
(62)
Adult
(54)
Medical Sciences
(54)
Materials Science
(52)
Oncology
(52)
Technology
(52)
Medicin Och Hälsovetenskap
(50)
Aged
(49)
Materials Science, Multidisciplinary
(47)
Immunology
(46)
Animals
(41)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)

The real-world impact of modern treatments on the survival of patients with metastatic melanoma

EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma

Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR⁻/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

Serological assessment of extracellular matrix (ECM) remodeling in relation to clinical response in metastatic melanoma patients treated with ipilimumab

Characterization and Comparison of 'Standard' and 'Young' Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma

T cell therapy for patients with advanced ovarian cancer: a pilot study in progress

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients

T cell recognition of breast cancer antigens

Functional characterization of Foxp3-specific spontaneous immune responses

Cellular based cancer vaccines: type 1 polarization of dendritic cells

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin‐Expressing Cells

Suchergebnisse filtern